COVID-19 Recombinant Hyperimmune, Leronlimab

Please read and agree to the disclaimer before watching this video.
. More lectures on drbeen.com

Looking to support my educational work? Donate here:
https://paypal.me/mobeensyed?locale.x=en_US

Leronlimab press release
https://www.cytodyn.com/newsroom/press-releases/detail/452/impressive-results-from-cytodyns-phase-2-covid-19-trial

https://www.cytodyn.com/newsroom/press-releases/detail/458/cytodyn-announces-clinically-significant-top-line-results
Capturing and Recreating Diverse Antibody Repertoires as Multivalent Recombinant Polyclonal Antibody Drugs
https://www.biorxiv.org/content/10.1101/2020.08.05.232975v1
Bay Area Biotech Company Develops Promising New Class Of Drug To Treat COVID-19 Patients
https://sanfrancisco.cbslocal.com/2020/08/10/a-promising-new-class-of-drug-for-covid-19-patients-recombinant-hyperimmunes/
Native vs random pairing

A natively paired antibody library yields drug leads with higher sensitivity and specificity than a randomly paired antibody library
Leronlimab symptom score
1.1     Endpoints and Assessments
1.1.1     Primary Efficacy Outcome Measure
The primary outcome (endpoint) measure is:
* Clinical Improvement as assessed by change in total symptom score (for fever, myalgia, dyspnea, and cough)
* Note: The total score per patient ranges from 0 to 12 points. Each symptom is graded from 0 to 3. [0=none, 1=mild, 2=moderate, and 3=severe]. ...

Disclaimer:
This video is not intended to provide assessment, diagnosis, treatment, or medical advice; it also does not constitute provision of healthcare services. The content provided in this video is for informational and educational purposes only.
Please consult with a physician or healthcare professional regarding any medical or mental health related diagnosis or treatment. No information in this video should ever be considered as a substitute for advice from a healthcare professional. ...
Disclaimer:
This video is not intended to provide assessment, diagnosis, treatment, or medical advice; it also does not constitute provision of healthcare services. The content provided in this video is for informational and educational purposes only.
Please consult with a physician or healthcare professional regarding any medical or mental health related diagnosis or treatment. No information in this video should ever be considered as a substitute for advice from a healthcare professional.

Видео COVID-19 Recombinant Hyperimmune, Leronlimab канала Drbeen Medical Lectures